The US FDA has cleared the first-in-class tyrosine kinase 2 (Tyk2) inhibitor as Sotyktu, and BMS says it now plans to launch the new drug later this month, aiming to mount a challenge to Amgen's $ ...

Bristol-Myers Squibb (BMS) has been steadily building its position in fibrotic diseases for some time, but accelerated its efforts this week with a $1.25 billion deal giving it the right to buy ...

An Internet of Things Agent for a JSON based protocol (with AMQP, HTTP and MQTT transports). This IoT Agent is designed to be a bridge between JSON and the NGSI interface of a context broker. It is ...

Internet of Things (IoT) Integration: Integration of BMS with IoT enables real-time monitoring of battery performance, health, and usage patterns. This integration offers opportunities for performance ...

Over the past few years, the real estate industry in Dubai has undergone a significant transformation in terms of technology ...

BMS-986368 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Epilepsy. According to GlobalData, Phase I drugs for Epilepsy have an 84% phase transition success rate ...

Disasters can strike without warning, and preparation is key to minimizing their impact on your commercial property. Abel Mendoza, a project construction manager at BMS CAT, emphasizes the importance ...

Swiss IoT module maker u-blox is to phase out its loss-making cellular IoT business, the firm has said. The division has over 200 employees; jobs are expected to go with its closure. It made revenue ...